About hansoh pharmaceutical group co. ltd. - HNSPF
Hansoh Pharmaceutical Group Co., Ltd. is a holding company, which engages in the research and development, production, and sale of a series of pharmaceutical products. Its products include oncology, anti-infective, CNS diseases; metabolic and other diseases. The company was founded by Hui Juan Zhong on December 2, 2015 and is headquartered in Shanghai, China.
HNSPF At a Glance
Hansoh Pharmaceutical Group Co., Ltd.
287 Xiangke Road
Shanghai, Shanghai 201210
| Phone | N/A | Revenue | 1.70B | |
| Industry | Pharmaceuticals: Major | Net Income | 607.47M | |
| Sector | Health Technology | 2024 Sales Growth | 19.464% | |
| Fiscal Year-end | 12 / 2025 | Employees | 8,989 | |
| View SEC Filings |
HNSPF Valuation
| P/E Current | 44.659 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 21.724 |
| Price to Sales Ratio | 7.769 |
| Price to Book Ratio | 3.36 |
| Price to Cash Flow Ratio | 20.12 |
| Enterprise Value to EBITDA | 16.61 |
| Enterprise Value to Sales | 5.898 |
| Total Debt to Enterprise Value | 0.002 |
HNSPF Efficiency
| Revenue/Employee | 189,525.403 |
| Income Per Employee | 67,578.865 |
| Receivables Turnover | 3.809 |
| Total Asset Turnover | 0.379 |
HNSPF Liquidity
| Current Ratio | 10.182 |
| Quick Ratio | 9.94 |
| Cash Ratio | 8.677 |
HNSPF Profitability
| Gross Margin | 90.984 |
| Operating Margin | 32.235 |
| Pretax Margin | 41.475 |
| Net Margin | 35.657 |
| Return on Assets | 13.506 |
| Return on Equity | 16.057 |
| Return on Total Capital | 15.397 |
| Return on Invested Capital | 16.008 |
HNSPF Capital Structure
| Total Debt to Total Equity | 0.411 |
| Total Debt to Total Capital | 0.409 |
| Total Debt to Total Assets | 0.372 |
| Long-Term Debt to Equity | 0.213 |
| Long-Term Debt to Total Capital | 0.212 |